This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury (FAIRTOP II)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Oklahoma
ClinicalTrials.gov Identifier:
NCT01270659
First received: January 4, 2011
Last updated: May 19, 2017
Last verified: May 2017
  Purpose
The primary purpose of this study is to evaluate fentanyl buccal tablet (FBT) for analgesia in comparison to standard analgesia, to determine if the FBT allows for faster achievement of "significant analgesia"

Condition Intervention Phase
Pain Drug: Fentanyl Drug: Oxycodone/acetaminophen Drug: oxycodone/acetaminophen Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Supportive Care
Official Title: Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain: The FAIRTOP II Trial

Resource links provided by NLM:


Further study details as provided by University of Oklahoma:

Primary Outcome Measures:
  • Median Time to Significant Analgesia (at Least 2 Units Decrease in Pain Level) [ Time Frame: 60 minutes ]
    Median time (in minutes) to 2 units decrease in pain level after drug administration. Patients were asked to rate their pain at every 5 minutes intervals from 0 to 60 minutes post drug administration. The 10-point verbally administered numeric pain rating scale (NPRS) was used to have patients rate their level of pain on a scale of 0 (no pain) to 10 (worst pain ever).


Secondary Outcome Measures:
  • Nausea Level [ Time Frame: every 5 minutes for the first 60 minutes ]

    Subjects' nausea level was recorded to determine how fentanyl buccal tablet compares to standard therapy in causing nausea. Treatment induced nausea and severity of nausea level was assessed.

    Nausea was assessed by a 10-point verbally administered scale. Patients rated their degree of nausea on a scale of 0 (no nausea) to 10 (worst nausea).

    At the beginning of the study, literature review found relatively little evidence guiding objective means to rate nausea, but there was some precedent for this approach (Warden C. Prehospital use of ondansetron reduces nausea and episodes of vomiting in adults and children over 12 years old [abstract]. Prehosp Emerg Care. 2007;11:132).


  • Number of Participants Experiencing Any Adverse Events [ Time Frame: Full 2 hours of the study period ]
    Occurrence of any adverse event.


Enrollment: 60
Study Start Date: May 2011
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low-FBT
Subject will receive FBT and placebo at a low dose
Drug: Fentanyl
Fentanyl buccal tablet 100 mcg once
Other Name: Fentora 100 mcg buccal tablet
Experimental: High-FBT
Subject will receive the high dose regimen of FBT and a high dose placebo
Drug: Fentanyl
Fentanyl buccal tablet 200 mcg once
Other Name: Fentora buccal tablet 200 mcg
Active Comparator: Low control
Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl "placebo"
Drug: Oxycodone/acetaminophen
Oxycodone/acetaminophen 5/325 mg once
Other Name: Percocet 5/325
Active Comparator: High control
Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl "placebo"
Drug: oxycodone/acetaminophen
Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time
Other Name: Percocet 5/325

Detailed Description:
The subjects/patients will be asked if they would desire a low dose or high dose pain medication regimen. The low dose (low-FBT) group will receive FBT at a dose of 100 mcg, as well as an oral (pill) placebo preparation. The low dose (low-control) group will receive an "inactive comparator" (lansoprazole rapidly-dissolving buccal 15mg, " FBT placebo") and a dose of 5/325 Percocet tablet (oxycodone/acetaminophen 5/325). The high dose (high-FBT) group will receive 200 mcg FBT plus 2 placebo tablets. The high dose (high-control) group will receive the "FBT placebo" and a dose of 2, 5/325 Percocet tablets.
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • pain sufficient to warrant medication stronger than acetaminophen (Tylenol) or aspirin
  • only if Emergency Department provider approves
  • a negative pregnancy test is required for participation for women of childbearing age

Exclusion Criteria:

  • If treating provider determines intravenous analgesia is required
  • allergy to acetaminophen or any opiate/opioid, or lansoprazole patients currently taking phenothiazines, CNS depressants (including alcohol), or if they have taken an monoamine oxidase inhibitor (MAOI) or selective serotonin reuptake inhibitor (SSRI) in the past two weeks
  • if patient has already been administered an opioid analgesic for their current injury
  • patients on chronic opioids therapy or a history of opioid abuse
  • breastfeeding mothers
  • patients who plan to drive home after their emergency department visit
  • history of phenylketonuria (due to phenylalanine in the formulation of the lansoprazole solutab)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01270659

Locations
United States, Oklahoma
Hillcrest Medical Center Emergency Department
Tulsa, Oklahoma, United States, 74104
Sponsors and Collaborators
University of Oklahoma
Investigators
Principal Investigator: Stephen H Thomas, MD MPH University of Oklahoma
Study Director: Annette O Arthur, PharmD University of Oklahoma
  More Information

Responsible Party: University of Oklahoma
ClinicalTrials.gov Identifier: NCT01270659     History of Changes
Other Study ID Numbers: 1774
Study First Received: January 4, 2011
Results First Received: April 6, 2017
Last Updated: May 19, 2017

Keywords provided by University of Oklahoma:
Fentanyl buccal tablet

Additional relevant MeSH terms:
Acetaminophen
Acetaminophen, hydrocodone drug combination
Fentanyl
Oxycodone
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on June 27, 2017